arrow
C

Catherine Sautès-Fridman

equipe labellisée ligue nationale contre le cancer
H指数:95
被引数:4.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues

作者更正: DC亚群和状态在人类的juxtatumoral和恶性组织中被解开

2025-12-160
OAAI
DC subsets and states unraveled across human juxtatumoral and malignant tissues

DC亚群和状态在人类的juxtatumoral和恶性组织中得到揭示

2025-12-080
PRE
Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics

多组学分析鉴定出两种具有不同信号通路和免疫特征的上皮样肉瘤分子亚型

2025-11-280
OAAI
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study

转移性透明细胞肾细胞癌中的Nivolumab: 来自NIVOREN getug-afu 26 2期研究的综合生物标志物分析

2025-11-110
PRE
Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) plus /- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial

在BIONIKK随机II期试验中,肉瘤样(S)和横纹肌样(R)成分(comp.)对转移性透明细胞肾细胞癌(mRCC)一线(L1)治疗中纳武利尤单抗(N)联合或单用伊匹木单抗(I)疗效的影响

2024-09-010
PRE
Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study

纳武利尤单抗(N)和伊匹木单抗(I)在随机II期BIONIKK研究中,用于转移性肾透明细胞癌(mRCC)患者的暴露-反应(E/R)关系。

2024-09-010
PRE
Timing and location dictate monocyte fate and their transition to tumor-associated macrophages

时间和位置决定单核细胞的命运及其向肿瘤相关巨噬细胞的过渡

2024-07-264
PRE
Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies

在抗检查点单克隆抗体治疗时代,b细胞和自身抗体介导的抗肿瘤免疫反应和自身免疫之间的复杂相互作用

2024-01-226
OAAI
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
2023-09-229
OAAI
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2023-06-1914
PRE
Roles of mesenchymal-like tumour cells and myofibroblastic cancer-associated fibroblasts in progression and therapeutic response of clear-cell renal cell carcinoma
2023-04-041
PRE
Guadecitabine plus ipilimumab in unresectable melanoma: Five-year follow-up and correlation with integrated, multi-omic analysis in the NIBIT-M4 trial
2023-04-040
PRE